Key Development
Imexpharm Pharmaceutical Joint Stock Company (Ticker: IMP) has officially announced significant leadership modifications within its Board of Directors (BOD) for the remainder of the 2023–2027 tenure. Effective June 23, 2026, Mr. Liu Daping and Ms. Liu Ning have been appointed as non-executive board members. Concurrently, the board accepted the resignations of former non-executive members Mr. Chung Suyong and Mr. Truong Minh Hung.
This executive reshuffle is the direct consequence of a major consolidation milestone: In early May 2026, Lian SGP Holding Pte. Ltd. deployed nearly VND 6,000 billion to acquire a controlling 67.87% stake in Imexpharm. Crucially, Lian SGP is a subsidiary of Livzon Pharmaceutical Group—a top 25 pharmaceutical conglomerate in China. The installation of the new board members reflects the majority shareholder’s strategy to directly steer and recalibrate the company’s future corporate direction.
Why It Matters
-
Formalized Governance Transition: The board reconfiguration marks the completion of the ownership handover, officially launching a new operational era under the direct governance of Livzon.
-
Internationalization of Operational Standards: Introducing leadership from a top 25 Chinese pharmaceutical manufacturer is expected to inject global commercialization practices into Imexpharm’s high-end EU-GMP manufacturing network.
-
Portfolio Diversification and R&D Synergy: Given Livzon’s extensive ecosystem spanning chemical entities, traditional medicine, and active pharmaceutical ingredients (APIs), Imexpharm is well-positioned to diversify beyond its historical reliance on antibiotics.
-
Reshaping the Pharma M&A Landscape: This trillion-dong transaction underscores the robust valuation and strategic appeal of Vietnam’s premium pharmaceutical assets to major regional healthcare aggregators.
Healthcare Insight Analysis
From the perspective of Healthcare Insight, the boardroom restructuring at Imexpharm represents more than a routine change of ownership; it signals a broader macroeconomic trend: The aggressive deployment of Asian healthcare capital (specifically from China and South Korea) targeting high-standard manufacturing infrastructure in Vietnam.
Imexpharm has long been regarded as a domestic market leader due to its significant capacity in EU-GMP compliant facilities. However, its primary operational challenges have historically centered on capacity utilization and global export scaling. By embedding executives from Livzon—a corporation with a footprint in over 30 countries including the US, EU, and Japan—Imexpharm gains two vital strategic advantages: a highly competitive, integrated API supply chain and immediate access to global distribution networks. This structural shift positions the company to move higher up the international pharmaceutical value chain.
Market Implications
-
Accelerated Inbound Consolidation: The trend of regional conglomerates acquiring controlling interests in tier-one domestic drugmakers (e.g., DHG Pharma, Pymepharco, and now Imexpharm) is consolidating ownership of the country’s top-tier production capabilities into foreign corporate hands.
-
Heightened ETC Market Competition: Backed by Livzon’s technological pipeline and extensive product registry, Imexpharm is poised to aggressively capture market share within Group 1 and Group 2 categories of public hospital procurement tenders.
-
Supply Chain Upgrading Pressures: This development will likely compel competing domestic pharmaceutical firms to either secure external strategic alliances or accelerate their own transitions toward EU-GMP and advanced regulatory standards to defend their market share.
Source: https://cafef.vn/bien-dong-nhan-su-tai-imexpharm-188260625113835793.chn